Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benchmarking Plasma Proteomics Workflows and Their Correlation to Clinical Routine Protein Assays.

Journal of proteome research·2026
Same author

Diastolic dysfunction and the risk of end-stage kidney disease among patients with non-dialysis-dependent chronic kidney disease.

The international journal of cardiovascular imaging·2026
Same author

Plasma growth differentiation factor-15 is associated with cardiovascular events in patients hospitalized for acute exacerbation of COPD.

Scientific reports·2026
Same author

Apolipoprotein M in Right Heart Failure.

medRxiv : the preprint server for health sciences·2025
Same author

HDL protein composition differs between young white European and South Asian men before and after weight gain.

Clinical science (London, England : 1979)·2025
Same author

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.

Research and practice in thrombosis and haemostasis·2025

Related Experiment Video

Updated: Jun 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

[Heparin-induced thrombocytopenia].

Christina Christoffersen1, Stefan Lethagen, Jens Peter Gøtze

  • 1Klinisk Biokemisk Afdeling, Rigshospitalet, DK-2100 København Ø. christina.christoffersen@rh.regionh.dk

Ugeskrift for Laeger
|March 17, 2009
PubMed
Summary

Heparin can cause immune-mediated thrombocytopenia (HIT). Early clinical assessment is crucial for diagnosis and initiating alternative anticoagulation, as lab tests may be delayed or inaccurate.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Heparin therapy is associated with Heparin-induced Thrombocytopenia (HIT), a serious immune-mediated condition.
  • Current laboratory diagnostics for HIT lack optimal specificity and sensitivity, potentially delaying diagnosis.
  • Clinical assessment plays a vital role in the early suspicion and management of HIT.

Purpose of the Study:

  • To highlight the importance of clinical evaluation in suspected cases of Heparin-induced Thrombocytopenia.
  • To emphasize the limitations of current laboratory diagnostic methods for HIT.
  • To guide the immediate management of patients when HIT is clinically suspected.

Main Methods:

  • Review of clinical findings and diagnostic challenges in Heparin-induced Thrombocytopenia.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Related Experiment Videos

Last Updated: Jun 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

  • Discussion of the utility of clinical scoring systems for HIT risk assessment.
  • Analysis of recommended treatment strategies for suspected HIT.

    • Main Results:

    • Clinical assessment and scoring systems can aid in the early identification of patients at risk for HIT.
    • Laboratory analyses for HIT antibodies may not be sufficiently rapid or accurate for timely diagnosis.
    • Prompt initiation of alternative anticoagulation is critical when HIT is suspected.

    Conclusions:

    • Clinical judgment is paramount in the initial management of potential Heparin-induced Thrombocytopenia.
    • Alternative anticoagulation should be started immediately upon clinical suspicion of HIT, preceding definitive laboratory confirmation.
    • Warfarin therapy and platelet infusions should be avoided in suspected HIT cases.